Radiolabeled monoclonal antibodies (for the radiology administrator).
Cheaper, faster, safer, these are not the attributes of 1993 automobiles, but criteria for new diagnostic tests in medicine. To achieve these characteristics, medicine is increasingly looking to biotechnology for answers. And the mother of all biotechnology is monoclonal antibody research. In past issues, Administrative Radiology published articles discussing the role of biotechnology in the development of radiopharmaceuticals used in nuclear medicine. In this issue, Richard Wahl, M.D., reviews, in plain talk, the current status and prospects for diagnostic imaging with radiolabeled monoclonal antibodies. Are there any such procedures of value today? Are there any that are FDA approved? Will there ever be such agents that are either useful or approved? If so, will any insurance carrier pay for them? For the answers to these and other "hot" questions, the reader is encouraged to continue on and read this month's Technology Review section.
Division of Nuclear Medicine, University of Michigan Medical Center, Ann Arbor.
R
R
Wahl
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D003952:Diagnostic Imaging / Q000295:instrumentation / Q000379:methods / Q000639:trends*; D006801:Humans; D006825:Hybridomas / Q000000981:diagnostic imaging*; D007239:Infections / Q000175:diagnosis; D009203:Myocardial Infarction / Q000175:diagnosis; D016719:Radioimmunodetection / Q000706:statistics & numerical data / Q000639:trends; D011872:Radiology Department, Hospital / Q000191:economics; D012051:Reimbursement Mechanisms; D013673:Technology Assessment, Biomedical; D013927:Thrombosis / Q000175:diagnosis; D014481:United States